FDA has approved Pfizer's BRAFTOVI combination for metastatic colorectal cancer with BRAF V600E mutation.

From Nasdaq: 2024-12-20 20:37:25

The FDA has approved Pfizer’s BRAFTOVI in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation. The approval was part of FDA’s Project FrontRunner for new cancer drugs for advanced disease. The decision was based on significant improvement in response rate and durability of response in treatment-naïve patients from the Phase 3 BREAKWATER trial. This accelerates the previous approval for BRAFTOVI in combination with cetuximab for adults with mCRC with a BRAF V600E mutation. Visit rttnews.com for more health news.



Read more at Nasdaq: FDA Grants Accelerated Approval To Pfizer’s BRAFTOVI Combination For Metastatic Colorectal Cancer